Pharming Group to participate in August investor conference
Pharming Group (NASDAQ:PHAR) announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference in Boston, USA.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Pharming Group (NASDAQ:PHAR) announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference in Boston, USA. CEO Fabrice Chouraqui will deliver a presentation on Tuesday, August 12, 2025, at 12:00 PM EDT/18:00 CEST.
Investors interested in one-on-one meetings with Pharming's management team can arrange them through the company's Investor Relations team or their Canaccord Genuity representative.
Details
News Market Reaction – PHAR
On Aug 4, the day this news came out, PHAR closed 11.77% above the previous close.
Data tracked by StockTitan Argus for the Aug 4 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Leiden, the Netherlands, August 4, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conference in the month of August:
- Canaccord Genuity 45th Annual Growth Conference, Boston, USA, August 12-13, 2025
Fabrice Chouraqui, Chief Executive Officer, will present on Tuesday, August 12 at 12:00pm EDT/18:00 CEST.
For more information about this conference, or to schedule a one-to-one meeting with Pharming’s management team, please contact Pharming’s Investor Relations team at investor@pharming.com or your Canaccord Genuity representative.
About Pharming Group N.V.
Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. We are commercializing and developing a portfolio of innovative medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific.
For more information, visit www.pharming.com and find us on LinkedIn.
For further public information, contact:
Pharming Group, Leiden, the Netherlands
Michael Levitan, VP Investor Relations & Corporate Communications
T: +1 (908) 705 1696
E: investor@pharming.com
FTI Consulting, London, United Kingdom
Simon Conway/Alex Shaw/Amy Byrne
T: +44 203 727 1000
LifeSpring Life Sciences Communication, Amsterdam, the Netherlands
Leon Melens
T: +31 6 53 81 64 27
E: pharming@lifespring.nl
Attachment
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.